Proactiveinvestors Interviews Bob Proulx on FDA Fast Track Status for MagSense® Imaging

Proactiveinvestors Interviews Bob Proulx on FDA Fast Track Status for MagSense® Imaging

Proactiveinvestors interviews Bob Proulx on what FDA’s designation of MagSense® imaging as a “breakthrough device” means for the company and its investors:
https://youtu.be/X4HLKyIl6Zo

Related Articles

Successful Placement of A$3M

Imagion Biosystems (ASX: IBX) (Company), is pleased to announce the Company has received $3 million of firm commitments through a highly successful capital raising. The

Read More

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.